These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25245327)

  • 1. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
    Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
    J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
    Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
    Front Immunol; 2021; 12():778459. PubMed ID: 34777395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
    de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
    J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
    Seung SK; Curti BD; Crittenden M; Walker E; Coffey T; Siebert JC; Miller W; Payne R; Glenn L; Bageac A; Urba WJ
    Sci Transl Med; 2012 Jun; 4(137):137ra74. PubMed ID: 22674552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
    Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
    Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
    Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
    J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
    Triozzi PL; Kim JA; Martin EW; Young DC; Benzies T; Villasmil PM
    J Clin Oncol; 1995 Feb; 13(2):482-9. PubMed ID: 7844609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
    Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
    J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
    Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
    Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
    Rosenberg SA; Yang JC; White DE; Steinberg SM
    Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
    Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
    J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
    J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
    Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
    Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
    Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.